Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer treatments like radiotherapy and chemotherapy often result in insufficient therapeutic effects and significant side effects on healthy cells. This necessitates the development of more targeted and effective therapeutic modalities.
Solution
LinqMed is developing radiopharmaceuticals that leverage the copper radioisotope 64Cu for both the diagnosis and treatment of cancer. This approach utilizes 64Cu's unique properties, including Auger electron emission for potent cellular targeting and positron emission for non-invasive PET imaging to visualize drug accumulation. By conjugating 64Cu to molecules with high affinity for cancer cells, LinqMed aims to create a new class of "visible" anti-cancer treatments. The company is advancing its lead candidate, 64Cu-ATSM, which targets hypoxic tumor environments, through clinical trials for malignant brain tumors.
Target Audience
The primary target audience includes oncologists, nuclear medicine physicians, and pharmaceutical researchers involved in the development and application of novel cancer therapies.
Features
- Development of radiopharmaceuticals utilizing the copper radioisotope 64Cu for dual diagnostic and therapeutic applications.
- 64Cu emits Auger electrons, enabling targeted cellular destruction with high energy.
- 64Cu's positron emission allows for non-invasive visualization of drug distribution via Positron Emission Tomography (PET).
- Proprietary platform for conjugating 64Cu to cancer-specific targeting molecules to create personalized treatments.
- Lead candidate, 64Cu-ATSM, designed to accumulate in hypoxic tumor cells, demonstrating preclinical efficacy in suppressing tumor growth and improving survival rates.
- Active Phase 1 clinical trial for 64Cu-ATSM in patients with malignant brain tumors.
- Focus on neuro-oncology and pancreatic cancer indications.